Loading company…
Leiden-based biotech developing IL-10 based non-opioid therapeutics for chronic pain, including complex regional pain syndrome.
Founded in 2018 and headquartered in Leiden, Netherlands, Synerkine Pharma B.V. develops interleukin 10 (IL-10) based therapeutics as non-opioid pain treatments, aimed at conditions such as Complex Regional Pain Syndrome. The therapeutics have received European Orphan Drug Designation and are marketed in Europe. On October 12, 2023, the company raised EUR 12.1 million in Series A funding led by Flerie Invest. CEO Hans Preusting leads the company.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in